Prime Medicine, Inc. Share Price & Technical Analysis
PRME · $2.97 (+0.68%)
Healthcare / Biotechnology
$2.97
+0.68%
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder cau…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
-14% return in May, 0% avg return in past 3 year May month.
-5% return in 2026, -12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 9% | 21% | -20% | 0% | -14% | – | – | – | – | – | – | – | -5% |
| 25 | -3% | -7% | -23% | -15% | -33% | 108% | 54% | -9% | 72% | -11% | -22% | -5% | 105% |
| 24 | -28% | 34% | -20% | -31% | 33% | -23% | 10% | -23% | -11% | 0% | -15% | -12% | -87% |
| 23 | -6% | -6% | -25% | 11% | -1% | 6% | 3% | -11% | -29% | -32% | 12% | 22% | -55% |
| 22 | – | – | – | – | – | – | – | – | – | -1% | -9% | 7% | -3% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$594.23M
P/E ratio
—
52W high
$6.94
52W low
$1.18
Volume
22,73,263
Beta
2.36
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Prime Medicine, Inc. share price today?
- Prime Medicine, Inc. (PRME) last traded around $2.97 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PRME have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PRME. Download the app for real-time alerts.
- How can I analyze Prime Medicine, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.